BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

Eisai And Nuvation Bio Advance Taletrectinib With EMA Validation For ROS1 Positive Lung Cancer

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company w...

March 30, 2026 | News

Akeso Advances IO 2.0 Plus ADC 2.0 Strategy With Phase II Trial Clearance In China

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that it has received clearance from the Center for Drug Evaluation (CDE) of China's ...

March 26, 2026 | News

Innovent Advances Tigulixostat Into Phase 3 To Challenge Standard Gout Therapy

Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality med...

March 24, 2026 | News

ImmunityBio Secures Macau Approval For ANKTIVA In BCG Unresponsive Non Muscle Invasive Bladder Cancer

Macau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patients with BCG-unresponsive NMIBC with CIS &plusm...

March 23, 2026 | News

GI Innovation Enters Clinical Supply Agreement With Johnson And Johnson To Advance Prostate Cancer Combination Therapy

GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a combination therapy...

March 23, 2026 | News

Dizal Reports ZEGFROVY Achieves Superior Progression Free Survival In Phase 3 WU KONG28 Trial For EGFR Exon20ins NSCLC

Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over pla...

March 23, 2026 | News

Excalipoint Therapeutics Secures 68.7 Million Dollar Seed Financing To Advance Next Generation T Cell Engager Platforms

Funding to advance proprietary T-cell engager platforms and pipeline of highly differentiated T-cell engager therapies targeting solid tumors and autoi...

March 20, 2026 | News

Innorna Secures FDA Clearance For First In Class mRNA Therapy IN026 In Refractory Gout

IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's propri...

March 19, 2026 | News

Australia Grants CTA For First In Human KMCAR T Cell Therapy Targeting Multiple Myeloma

Clinical Trial Approval (CTA) granted by Australia’s Therapeutic Goods Administration (TGA) for KMCAR™ T-cell, a first-in-human CAR-T cell th...

March 18, 2026 | News

Celltrion Expands US Immunology Portfolio With AVTOZMA Subcutaneous Tocilizumab Biosimilar

AVTOZMA® (tocilizumab-anoh) is among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations app...

March 17, 2026 | News

Meiji Seika Pharma Initiates Phase I Trial Of ME3241 PD 1 Agonist Antibody For Autoimmune Diseases

Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced that it has in...

March 12, 2026 | News

Vaxcellbio And Reber Genetics Form Strategic Partnership To Expand Companion Animal Immunotherapy Across Asia

Vaxcellbio (CEO Je-Jung Lee, MD, PhD), a leading immuno-oncology company, announced on Wednesday that it has signed a Master Partnership Agreement (MPA) wi...

March 12, 2026 | News

Leads Biolabs Doses First Patient In Phase II Trial Of PD L1 4 1BB Bispecific Antibody For Esophageal Cancer

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026 that the first patient has bee...

March 10, 2026 | News

Akeso Reports Durable Long Term Survival Benefit Of Cadonilimab In Advanced Cervical Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II ...

March 06, 2026 | Report

Stay Connected